Agomab Therapeutics NV (AGMB) Price Prediction & ForecastAGMBAgomab Therapeutics NV

Alphio's AGMB stock price prediction model matches the current Agomab Therapeutics NV tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $9.07 (+0.26%). The 1-week path is $9.06 (+0.13%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Agomab Therapeutics is a good buy right now due to its promising clinical developments and strong analyst support. The stock is currently priced at $9.05, with a significant upside potential indicated by analyst targets ranging from $34 to $60. Additionally, the recent Phase 2b trial initiation for its drug Ontunisertib in Crohn's disease positions the company well in a market projected to grow significantly, which is a strong positive catalyst. However, the company is currently facing a negative net income of -11.73 million EUR for Q4 2024, which represents a risk to its financial stability.

Agomab Therapeutics NV (AGMB) last closed at $9.05, losing -2.27%. These facts feed the 1-day and 1-week AGMB price prediction above.